Caribou to halt CAR-T work, lay off staff amid ‘challenging’ funding climate

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 07 Oct, 15:37 UTC

Despite having an allogeneic cell therapy prospect that’s ready for late-stage testing in lymphoma, Caribou couldn’t secure funding to support the effort and will now pursue “strategic alternatives” instead.